Cargando…

Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer

SIMPLE SUMMARY: Androgen deprivation therapy alone is commonly performed for metastatic prostate cancer but is generally not recommended for the treatment of high-risk localized or locally advanced prostate cancer. In this article, we will discuss the position, indications, and future possibilities...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwamoto, Hiroaki, Izumi, Kouji, Makino, Tomoyuki, Mizokami, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997146/ https://www.ncbi.nlm.nih.gov/pubmed/35406575 http://dx.doi.org/10.3390/cancers14071803

Ejemplares similares

Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer
por: Makino, Tomoyuki, et al.
Publicado: (2021)

Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells
por: Izumi, Kouji, et al.
Publicado: (2019)

Editorial for the Special Issue on High-Risk Localized and Locally Advanced Prostate Cancer
por: Izumi, Kouji
Publicado: (2023)

Efficacy and safety of keishibukuryogan, a traditional Japanese Kampo medicine, for hot flashes in prostate cancer patients receiving androgen deprivation therapy
por: Shigehara, Kazuyoshi, et al.
Publicado: (2020)

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
por: Makino, Tomoyuki, et al.
Publicado: (2021)

Combination of Sarcopenia and Hypoalbuminemia Is a Poor Prognostic Factor in Surgically Treated Nonmetastatic Renal Cell Carcinoma
por: Makino, Tomoyuki, et al.
Publicado: (2023)

Efficacy of keishibukuryogan for hot flashes in prostate cancer patients receiving androgen deprivation therapy: a sub-analysis focusing on hormonal and cytokine levels
por: Shigehara, Kazuyoshi, et al.
Publicado: (2023)

Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer
por: Golabek, Tomasz, et al.
Publicado: (2016)

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL
por: Iwamoto, Hiroaki, et al.
Publicado: (2019)

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy
por: Tomioka, Atsushi, et al.
Publicado: (2015)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review
por: Kadomoto, Suguru, et al.
Publicado: (2020)

The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer
por: Gunner, Charlotte, et al.
Publicado: (2016)

Comparison of the Prognostic Value of Inflammatory and Nutritional Indices in Nonmetastatic Renal Cell Carcinoma
por: Makino, Tomoyuki, et al.
Publicado: (2023)

A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age
por: Iwamoto, Hiroaki, et al.
Publicado: (2020)

Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination
por: Lee, Sung Uk, et al.
Publicado: (2017)

Is the C-C Motif Ligand 2–C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?
por: Iwamoto, Hiroaki, et al.
Publicado: (2020)

Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments
por: Payne, H, et al.
Publicado: (2011)

Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines
por: Machioka, Kazuaki, et al.
Publicado: (2018)

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
por: Mason, Malcolm D., et al.
Publicado: (2015)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

α-Trifluoromethyl Chalcones as Potent Anticancer Agents for Androgen Receptor-Independent Prostate Cancer
por: Saito, Yohei, et al.
Publicado: (2021)

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
por: Warde, Padraig, et al.
Publicado: (2011)

Influence of Timing Between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients With Localized, High-Risk Prostate Cancer
por: McCall, Neal S., et al.
Publicado: (2021)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

Androgen replacement therapy for cancer‐related symptoms in male: result of prospective randomized trial (ARTFORM study)
por: Izumi, Kouji, et al.
Publicado: (2021)

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

Epidemiology and Prevention of Renal Cell Carcinoma
por: Makino, Tomoyuki, et al.
Publicado: (2022)

Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer
por: Lu, Yu-Cheng, et al.
Publicado: (2022)

CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells
por: Natsagdorj, Ariunbold, et al.
Publicado: (2018)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

AB37. The combination of I brachytherapy with intermittent androgen deprivation in treating locally advanced prostate cancer
por: Huang, Yi
Publicado: (2014)

Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer
por: Saito, Yohei, et al.
Publicado: (2021)

C‐C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment
por: Urata, Satoko, et al.
Publicado: (2018)

Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
por: Lilleby, Wolfgang, et al.
Publicado: (2015)

Nationwide Industry-Led Community Exercise Program for Men With Locally Advanced, Relapsed, or Metastatic Prostate Cancer on Androgen-Deprivation Therapy
por: Schumacher, Oliver, et al.
Publicado: (2022)

Tumor necrosis factor‐α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation
por: Maolake, Aerken, et al.
Publicado: (2018)

The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada
por: Davis, Margot K., et al.
Publicado: (2015)

Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men
por: Nakagawa, Ryunosuke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bu4s1h6rh3nenactufonc6g02p